About BCAA
Generic BCAA blend covering products that list 'BCAA' or 'BCAAs' without breaking out leucine/isoleucine/valine separately. Most commercial blends use a 2:1:1 ratio (the ratio found in muscle tissue and validated in most RCTs). Some products use higher leucine ratios (4:1:1, 8:1:1) marketed as 'optimized for MPS' — evidence for ratios beyond 2:1:1 is mixed. BCAAs alone are inferior to complete protein (whey, casein) for muscle protein synthesis because MPS requires all essential amino acids: Jackman et al. 2017 (PMID 28638350) showed 5.6 g BCAAs post-resistance-exercise raised myofibrillar MPS only ~22% over placebo, whereas comparable-leucine doses from ~20 g whey raise MPS by ~50–70% in separate trials (Witard 2014, Churchward-Venne 2012). Use case is best supported for intra-workout fatigue reduction and exercise in a fasted state when complete protein isn't available.
What BCAA supports
- Triggers muscle protein synthesis via leucine-mediated mTOR activation
- Reduces perceived exertion and central fatigue during prolonged exercise
- Supports post-exercise recovery when complete protein intake is delayed
How much BCAA to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
5000–10000
mg
Total BCAA blend, typically dosed at 5–10 g (standard 2:1:1 leucine:isoleucine:valine). 5 g delivers ~2.5 g leucine — at the threshold for maximal mTOR/MPS activation. Higher doses (8–10 g) common in intra-workout products.
Clinical evidence
Moderate clinical evidence. Established effect on MPS (driven by leucine content), but inferior to complete protein at equivalent leucine doses. Strongest evidence is for fatigue reduction during prolonged or fasted exercise.
Examine.com